UBXN1: The Potential Drug Target and Biomarker (G51035)

Target Name: UBXN1

NCBI ID: G51035

UBXN1

UBXN1: The Potential Drug Target and Biomarker

Uncovering the Potential of UBXN1 as a Drug Target and Biomarker

UBXN1, or UBXN1 protein, is a protein that is expressed in various tissues and cells throughout the body. Its primary function is to regulate the growth and differentiation of tissues, including brain and spinal cord development.UBXN1 has also been shown to play a key role in the development and progression of various diseases, including cancer.

The search for new drug targets and biomarkers has led to the identification of UBXN1 as a promising target for drug development.UBXN1 has been shown to be involved in several cellular processes that are crucial for disease progression, including cell proliferation, migration, and invasion.

In addition, UBXN1 has also been shown to play a role in the regulation of cellular signaling pathways, including the TGF-β pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival, and is often disrupted in various diseases, including cancer.

UBXN1 has also been shown to be involved in the regulation of theNotch signaling pathway. This pathway is involved in the regulation of cell survival and proliferation, and is often disrupted in various diseases, including neurodegenerative disorders.

The identification of UBXN1 as a potential drug target and biomarker has led to a significant increase in the number of studies that have investigated its role in disease. These studies have provided a detailed understanding of the functions of UBXN1 and its potential as a drug target.

UBXN1 has also been shown to be involved in the regulation of cellular processes that are crucial for the development and progression of various diseases, including cancer. For example, studies have shown that UBXN1 is involved in the regulation of cell proliferation and migration, which are crucial for the development of cancer.

In addition, UBXN1 has also been shown to play a role in the regulation of cellular signaling pathways, including the TGF-β pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival, and is often disrupted in various diseases, including cancer.

UBXN1 has also been shown to be involved in the regulation of theNotch signaling pathway. This pathway is involved in the regulation of cell survival and proliferation, and is often disrupted in various diseases, including neurodegenerative disorders.

The identification of UBXN1 as a potential drug target and biomarker has led to a significant increase in the number of studies that have investigated its role in disease. These studies have provided a detailed understanding of the functions of UBXN1 and its potential as a drug target.

UBXN1 has also been shown to be involved in the regulation of cellular processes that are crucial for the development and progression of various diseases, including cancer. For example, studies have shown that UBXN1 is involved in the regulation of cell proliferation and migration, which are crucial for the development of cancer.

In addition, UBXN1 has also been shown to play a role in the regulation of cellular signaling pathways, including the TGF-β pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival, and is often disrupted in various diseases, including cancer.

UBXN1 has also been shown to be involved in the regulation of theNotch signaling pathway. This pathway is involved in the regulation of cell survival and proliferation, and is often disrupted in various diseases, including neurodegenerative disorders.

The potential drug target and biomarker that is UBXN1 has led to a significant increase in the number of studies that have investigated its role in disease. These studies have provided a detailed understanding of the functions of UBXN1 and its potential as a drug target.

UBXN1 has also been shown to be involved in the regulation of cellular processes that are crucial for

Protein Name: UBX Domain Protein 1

Functions: Ubiquitin-binding protein that plays a role in the modulation of innate immune response. Blocks both the RIG-I-like receptors (RLR) and NF-kappa-B pathways. Following viral infection, UBXN1 is induced and recruited to the RLR component MAVS. In turn, interferes with MAVS oligomerization, and disrupts the MAVS/TRAF3/TRAF6 signalosome. This function probably serves as a brake to prevent excessive RLR signaling (PubMed:23545497). Interferes with the TNFalpha-triggered NF-kappa-B pathway by interacting with cellular inhibitors of apoptosis proteins (cIAPs) and thereby inhibiting their recruitment to TNFR1 (PubMed:25681446). Prevents also the activation of NF-kappa-B by associating with CUL1 and thus inhibiting NF-kappa-B inhibitor alpha/NFKBIA degradation that remains bound to NF-kappa-B (PubMed:28152074). Interacts with the BRCA1-BARD1 heterodimer and regulates its activity. Specifically binds 'Lys-6'-linked polyubiquitin chains. Interaction with autoubiquitinated BRCA1 leads to the inhibition of the E3 ubiquitin-protein ligase activity of the BRCA1-BARD1 heterodimer (PubMed:20351172). Component of a complex required to couple deglycosylation and proteasome-mediated degradation of misfolded proteins in the endoplasmic reticulum that are retrotranslocated in the cytosol

The "UBXN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBXN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets